Position
Fidelity in Akebia Therapeutics, Inc.
Back to the book · All holders of AKBA
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$333.8K$1.39 → $1.14
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 1.13M | $1.81M | — | — | — | 0.0% |
| Q1 2026 | 1.34M | $1.86M | $1.39 | −$247.6K | $291.5K | 0.0% |
| Q2 2026 | 1.87M | $2.13M | $1.14 | −$333.8K | $610.7K | 0.0% |